Real-world burden of hypertrophic cardiomyopathy on healthcare use and health-related quality of life in Italy, Spain, and the United States

Le résumé fourni par la source

Hypertrophic cardiomyopathy (HCM) is a chronic, progressive, genetic heart disease characterized by hypercontractility and hypertrophy. As treatment options evolve, characterizing the existing healthcare needs and health-related quality of life (HRQoL) for patients with HCM is important. Data were derived from the Adelphi Real World HCM Disease Specific Programme, a cross-sectional survey in Italy, Spain, and the United States. Physicians reported demographic and clinical characteristics; patients completed the Kansas City Cardiomyopathy Questionnaire (KCCQ-23), EQ-5D-5L and EQ-VAS, and the Work Productivity and Activity Impairment (WPAI) questionnaire. Outcomes were statistically compared by New York Heart Association (NYHA) class or KCCQ clinical summary score (KCCQ-CSS) to assess impact of disease severity. Patient mean age was 56.5 ± 14.8 years; 60.7% were male, and 78.3% had NYHA class II disease. Patients most commonly received beta blockers (88.4%) and diuretics (31.8%). HCM-related hospitalizations were reported for 25.8% of patients, increasing with higher NYHA or lower KCCQ-CSS. Mean EQ-5D-5L was 0.85, while EQ-VAS was 75.0, both decreasing with higher NYHA class or lower KCCQ-CSS. Overall work impairment and activity impairment (WPAI) were 16.1% and 26.6%, respectively, increasing with higher NYHA class or lower KCCQ-CSS. Our data show a significant remaining symptom burden and healthcare resource utilization (HCRU), as well as impact on HRQoL, work productivity, and daily activities, despite treatment intervention across a commonly applied measure of disease severity in HCM. These findings underscore the need for new treatments that can reduce HCRU and improve HRQoL of patients with HCM.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.